BBANTWi012-A-4

iPSC_FB_F19901C3_TTN_E357_V33467*_N33456N_C3

General

Cell Line

hPSCreg name BBANTWi012-A-4
Cite as:
BBANTWi012-A-4 (RRID:CVCL_E3QY)
Alternative name(s)
iPSC_FB_F19901C3_TTN_E357_V33467*_N33456N_C3
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 10th May 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Biobank Antwerpen (BBANTW)
Owner Center of Medical Genetics Antwerp (CMGANT)
Distributors
Derivation country Belgium

External Databases

BioSamples SAMEA115501575
Cellosaurus CVCL_E3QY

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA115545255

Ethics

Also have a look at the ethics information for the parental line BBANTWi012-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

The source cell information can be found in the parental cell line BBANTWi012-A.

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
Unknown
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
Medium Essential 8™ Flex
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SOX2
Yes
TRA 1-60
Yes
TRA 1-81
Yes
POU5F1 (OCT-4)
Yes
NANOG
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
SOX17
Yes
FOXA2
Yes
CXCR4
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
NKX2-5
Yes
HAND1
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
PAX6
Yes
HES5
Yes
MAP2
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY. No clinically significant abnormalities observed.
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
SNP typing array
Genotyped with Illumina's HumanCytoSNP-12 v2.1. No clinically significant CNVs observed.

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • Congestive Cardiomyopathy
  • Dilated Cardiomyopathy
Genetic modifications
TTN (target)
Variant
TTN c.100373delT
TTN (p.Val33467*)
Heterozygous
Genetic modifications not related to a disease
TTN (target)
Variant
TTN c.100368C>T
TTN p.Asn33456Asn
Heterozygous